Campus Transformation | NYU Langone Health
The campus transformation project is dramatically reshaping NYU Langone through major new construction, renovations, and expansions.
PET/CT Scans | NYU Langone Health
NYU Langone offers PET/CT scans to diagnose illness, evaluate treatments, and assess the recurrence of many conditions, including cancer.
NYU Langone Cardiology Associates—East Patchogue | NYU Langone Health
Doctors at NYU Langone Cardiology Associates—East Patchogue offer high-quality care for a variety of conditions that affect the heart.
CBYL719F12201: EPIK-P2 Phase II double-blind study w/ upfront 16-week randomized placebo-controlled period to assess efficacy safety & pharmacokinetics of alpelisib (BYL719) in pediatric & adult patients w/ PIK3CA-related overgrowth spectrum (PROS)
This study will be the first prospective study of alpelisib in participants with PROS. Local overgrowth or hemihypertrophy, mostly progressive, is the most frequently observed manifestation of the disease, often causing functional and/or mobility impairment andreduction in health related quality of life. The first experience with alpelisib in overgrowth related to mutation in PIK3CA gene provides the direct evidence of clinical improvement in participants supporting PIK3CA inhibition as a promising therapeutic strategy in participants with PROS. PROS is a serious condition with no approved pharmacological treatment targeting the underlying cause of the disease. Current therapy includes debulking surgery, amputation, and/or endovascular occlusive procedures and mainly addresses symptoms and complications of the disease. There is a high unmet medical need for an effective systemic treatment.The purpose of this study is to assess the efficacy, safety/tolerability and evaluate pharmacokinetics (PK) of alpelisib in participants of different ages with confirmed diagnosis of PROS. As the disease continues throughout the participant life and may be diagnosed at different time points (Keppler-Noreuil et al 2014), the study will enroll adult participants (Group 1; treated with film-coated tablets (FCT)), 6-17 years old pediatric participants (Group 2; treated with FCT), and two exploratory sets of 2-5 years old pediatric participants (Group 3 treated with granules and Group 4 treated with FCT).Group 3 will be enrolled after the completion of the primary analysis when the efficacy, safety and PK data will be available from the participants in Groups 1 and 2 in addition to the data from Group 4 as available, in order to select the recommended dose forparticipants in Group 3. Recruitment of participants in Group 3 will start only after submission and approval of a Substantial Global Protocol Amendment specific to this group. Group 4 will be enrolled before Group 3 and immediately after implementation of this Global Protocol Amendment 01.
Stroke | NYU Langone Health
The specialists at NYU Langone’s Comprehensive Stroke Care Center diagnose stroke and provide rapid, effective treatment.
Medication for Stroke | NYU Langone Health
NYU Langone stroke specialists may prescribe medication to manage an ischemic stroke or transient ischemic attack.
Medications & Dietary Changes for Kidney Stones | NYU Langone Health
Doctors at NYU Langone work together to prevent and treat kidney stones, prescribing medications and recommending dietary changes.
Center for the Study of Eosinophilic Esophagitis | NYU Langone Health
Experts at NYU Langone’s Center for the Study of Eosinophilic Esophagitis help children manage symptoms that make eating difficult.
Chemotherapy for Hodgkin Lymphoma | NYU Langone Health
NYU Langone doctors prescribe a combination of chemotherapy drugs for Hodgkin lymphoma.
Pediatric Intensive Care Unit Team | NYU Langone Health
Experts at Hassenfeld Children's Hospital at NYU Langone provide the highest levels of care in the pediatric intensive care unit.